FY2024 Earnings Estimate for Nyxoah Issued By HC Wainwright

Nyxoah S.A. (NASDAQ:NYXH) – Research analysts at HC Wainwright dropped their FY2024 earnings estimates for shares of Nyxoah in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst E. White now forecasts that the company will earn ($2.00) per share for the year, down from their previous estimate of ($1.65). HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Nyxoah’s current full-year earnings is ($1.94) per share. HC Wainwright also issued estimates for Nyxoah’s Q4 2024 earnings at ($0.54) EPS, FY2025 earnings at ($1.28) EPS and FY2026 earnings at $0.44 EPS.

Several other research firms have also commented on NYXH. Oppenheimer lowered their price target on shares of Nyxoah from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 target price on shares of Nyxoah in a report on Tuesday, November 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $17.00.

Nyxoah Stock Down 3.6 %

NYXH stock opened at $8.80 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 5.16. The firm’s fifty day simple moving average is $8.99 and its 200-day simple moving average is $8.77. Nyxoah has a 12 month low of $4.00 and a 12 month high of $20.00. The company has a market capitalization of $219.47 million, a P/E ratio of -4.88 and a beta of 1.45.

Institutional Trading of Nyxoah

Several institutional investors have recently bought and sold shares of NYXH. Iron Triangle Partners LP acquired a new position in shares of Nyxoah during the 1st quarter worth about $3,413,000. Ikarian Capital LLC purchased a new stake in Nyxoah during the 1st quarter worth approximately $684,000. CVI Holdings LLC acquired a new position in shares of Nyxoah during the second quarter valued at approximately $1,292,000. Finally, Kovack Advisors Inc. purchased a new position in shares of Nyxoah in the third quarter valued at approximately $96,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.